Marburg Hemorrhagic Fever Drug Market 2020-2025 | Evolving Opportunities with Leading Players - GSK, Immunovaccine, Sarepta Therapeutics, Tekmira Pharma, Vaxart

Overview of Global Marburg Hemorrhagic Fever Drug Market:

This report provides in-depth study of "Global Marburg Hemorrhagic Fever Drug Market 2020" using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Marburg Hemorrhagic Fever Drug Market report also provides an in-depth survey of key players in the market organization.

According to the market research study, the Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. Ebola viruses (EBOV) has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90% dramatically highlight its lethal potential.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/92404 .

Firstly, the report provides a basic overview of the Market including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major Market players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2020-2025 market shares for each company.

Through the statistical analysis, the report depicts the international Marburg Hemorrhagic Fever Drug Market including capacity, production, production value, cost/profit, supply/demand and global import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Marburg Hemorrhagic Fever Drug industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

In the end, the report makes some important proposals for a new project of Marburg Hemorrhagic Fever Drug Market before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2025 global Marburg Hemorrhagic Fever Drug market covering all important parameters.

Global Key Vendors:

1 GlaxoSmithKline plc

2 Immunovaccine, Inc.

3 Integrated BioTherapeutics, Inc.

4 Sarepta Therapeutics, Inc.

5 Tekmira Pharmaceuticals Corp.

6 Vaxart and More.................

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global Marburg Hemorrhagic Fever Drug Market Report 2020" @ https://www.businessindustryreports.com/buy-now/92404/single .

Product Type Segmentation

1 Marburg Vaccine

2 AVI-7288

3 TKM-Marburg

4 Others

Industry Segmentation

1 Clinic

2 Hospital

3 Others

Global Healthcare Industry News:

GlaxoSmithKline (GSK) (April 29, 2020) - FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status - GlaxoSmithKline plc today announced the US Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status. Until now, only 20% of women with ovarian cancer, those with a BRCA mutation (BRCAm), were eligible to be treated with a PARP inhibitor as monotherapy in the first-line maintenance setting.[i]

Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: "Women with advanced ovarian cancer have a five-year survival rate of less than 50%. This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend the time it takes for their cancer to progress."

Zejula is the only once-daily PARP inhibitor approved in the US as monotherapy for women with advanced ovarian cancer beyond those with BRCAm disease in the first-line and recurrent maintenance treatment settings, as well as late-line primary treatment settings.

This new indication is supported by data from the phase III PRIMA study (ENGOT-OV26/GOG-3012), which enrolled patients with newly diagnosed advanced ovarian cancer following a complete or partial response to platinum-based chemotherapy regardless of biomarker status. The PRIMA study enrolled women who had higher risk of disease progression, a population with high unmet needs and limited treatment options.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/92404 .

Major Points in Table of Contents:

Global Marburg Hemorrhagic Fever Drug Market Report 2020

1 Marburg Hemorrhagic Fever Drug Product Definition

2 Global Marburg Hemorrhagic Fever Drug Market Manufacturer Share and Market Overview

3 Manufacturer Marburg Hemorrhagic Fever Drug Business Introduction

4 Global Marburg Hemorrhagic Fever Drug Market Segmentation (Region Level)

5 Global Marburg Hemorrhagic Fever Drug Market Segmentation (Product Type Level)

6 Global Marburg Hemorrhagic Fever Drug Market Segmentation (Industry Level)

7 Global Marburg Hemorrhagic Fever Drug Market Segmentation (Channel Level)

8 Marburg Hemorrhagic Fever Drug Market Forecast 2020-2025

9 Marburg Hemorrhagic Fever Drug Segmentation Product Type

10 Marburg Hemorrhagic Fever Drug Segmentation Industry

11 Marburg Hemorrhagic Fever Drug Cost of Production Analysis

12 Conclusion

................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.